Histogen to Explore Strategic Alternatives
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners, LLC, to act as a strategic advisor in this process.
Related news for (HSTO)
- Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Second Adjournment of Special Meeting of Stockholders
- Histogen Announces Adjournment of Special Meeting of Stockholders
- Histogen Announces Board Approval of Complete Liquidation and Dissolution